ND-023

N/A

Report date: 2023/03/12 15:48:24

Base Information

Drug NameND-023
Drug Alias NameND-023
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNumab Therapeutics AgOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOno Pharmaceutical Co LtdNumab Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A